en · de · es · fr · pt
peptide-index.peptides6823.com › Info › Research And Regulatory Status — 2026 Update

Research And Regulatory Status — 2026 Update

By Editorial Desk · published 2025-08-31 · last reviewed 2025-10-05 · Info

synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-10-05 and is reviewed periodically as new material appears.

Research and Regulatory Status

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

Identity and Molecular Context

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

Aod-9604 at a glance

PropertyValueNotes
Primary research areaObesity and metabolic regulationStudied in cell, animal, and human models
Highest reported trial phasePhase IIPublic summaries describe mixed results
Common route in trialsSubcutaneous injectionTypical for peptide therapeutics
Regulatory example2013 Australian anti-doping reviewClassification was debated at the time
Approval statusNot approved as a human medicineStatus can change by jurisdiction

Handling And Analytical Properties

Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.

Related pages on this site

Identity And Research Background

AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

Mechanism and Regulatory Status

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Further detail

, the first step is to linearise around the disease-free equilibrium (DFE), but for the infected subsystem of non-linear ODEs which describe the production of new infections and changes in state among infected individuals. Epidemiologically, the linearisation reflects that

24 June – Dunedin Airport receives its first international flight—a Jetstar flight from Gold Coast Airport—since the start of the COVID-19 pandemic in 2020. 25 June – Nelson Hospital switches from coal to landfill gas as part of a nationwide decarbonisation shift. 26 June: A state of emergency is declared in the Wairau-Awatere Ward of Marlborough due to heavy rain. 32 Māori land trusts (representing over 150,000 landowners, hapu (sub-groups) and iwi (tribes) file legal proceedings against the New Zealand Crown at the High Court urging the Government to stop the degradation of fresh water, honour the Treaty of Waitangi and Māori rights over water and geothermal resources. The New Zealand Government passed legislation designating the Independent Children's Monitor as an independent Crown entity, dissolving the Children and Young People's Commission and reinstating the Children's Commissioner. 27 June: A state of emergency is declared in Nelson and Tasman due to heavy rain and flooding . Residents of parts of Spring Creek are asked to evacuate in response to concerns that heavy overnight rain could cause the Wairau River to flood. New Zealand First list Member of Parliament Tanya Unkovich resigns to concentrate on work in the private sector. 28 June – A tornado in Waitara damages 11 homes. 29 June — The Government's sentencing reforms, which reduces sentencing discounts and encourages cumulative sentencing, comes into effect. 30 June – Oji Fibre Solutions ceases paper production operations at its Kinleith Mill in Tokoroa, affecting 230 jobs.

=== Detectors === The detectors used in surface plasmon resonance convert the photons of light reflected off the metallic film into an electrical signal. A position sensing detector (PSD) or charged-coupled device (CCD) may be used to operate as detectors.

Critic Robert Christgau called it "an ominous, obsessive, tongue-in-cheek country-rock synthesis, absorbing rural and urban, traditional and contemporary, at point of impact." Parsons suffered from fear of flying and the band toured via train. The band members lost most of their money in a perpetual poker game and their concerts were met with bewilderment. Parsons was taking psilocybin and cocaine, so his performances were erratic. The most successful appearance was in Philadelphia, where the group opened for the reconstituted Byrds. Midway through their set, Parsons joined the headline act and fronted his former group on renditions of "Hickory Wind" and "You Don't Miss Your Water". After returning to Los Angeles, the group recorded "The Train Song", written during an increasingly infrequent songwriting session on the train and produced by 1950s R&B legends Larry Williams and Johnny "Guitar" Watson. Despite a request from the Burritos that the remnants of their publicity budget be diverted to the promotion of the single, it also flopped. During this period, Ethridge departed, saying that he did not share Parsons' and Hillman's affinity for country music. He was replaced by lead guitarist Bernie Leadon, while Hillman reverted to bass. By this time, Parsons's drug use had increased to the point where new songs were rare, and much of his time was spent partying with the Rolling Stones, who were in America finishing Let It Bleed. As the Stones prepared to play the nation's largest venues, the Burritos played to dwindling nightclub audiences.

Sources: en.wikipedia.org

Supporting material

The precipitation of albumin is done by reducing the pH to 4.8, near the pH of the proteins, and maintaining the ethanol concentration at 40%, with a protein concentration of 1%. Thus, only 1% of the original plasma remains in the fifth fraction. When the ultimate goal of plasma processing is a purified plasma component for injection or transfusion, the plasma component must be highly pure. The first practical large-scale method of blood plasma fractionation was developed by Edwin J. Cohn during World War II. it's known as the Cohn process (or Cohn method). This process is also known as cold ethanol fractionation, as it involves gradually increasing the concentration of ethanol in the solution at 5 °C and 3 °C. The Cohn Process exploits differences in plasma proteins properties, specifically, the high solubility and low pI of albumin. As the ethanol concentration is increased in stages from 0 to 40%, the pH declines from neutral (pH ~ 7) to about 4.8, which is near the pI of albumin. At each stage, proteins are precipitated out of the solution and removed. The final precipitate is purified albumin. Several variations to this process exist, including an adapted method by Nitschmann and Kistler that uses fewer steps, and replaces centrifugation and bulk freezing with filtration and diafiltration. Some newer methods of albumin purification add additional purification steps to the Cohn process and its variations. Chromatographic albumin processing emerged in the 1980s, however, it was not widely adopted until later due to the scarity of large-scale chromatography equipment.

Envenomation resulted in 57,000 human deaths in 2013, down from 76,000 deaths in 1990. Venoms, found in over 173,000 species, have potential to treat a wide range of diseases, explored in over 5,000 scientific papers. In medicine, snake venom proteins are used to treat conditions including thrombosis, arthritis, and some cancers. Gila monster venom contains exenatide, used to treat type 2 diabetes. Solenopsins extracted from fire ant venom has demonstrated biomedical applications, ranging from cancer treatment to psoriasis. A branch of science, venomics, has been established to study the proteins associated with venom and how individual components of venom can be used for pharmaceutical means.

GOSR2-related progressive myoclonus ataxia, also known as Progressive myoclonic epilepsy type 6, is a rare genetic type of progressive myoclonus ataxia which is characterized by progressive myoclonic epilepsy with an early onset which is associated with generalized tonic-clonic seizures, petit mal seizures, and drop attacks, variable degrees of scoliosis, areflexia, high levels of creatine kinase serum, and late-onset cognitive decline. According to OMIM, only 12 cases have been described in medical literature.

=== Techdirt === In January 2017, Ayyadurai, again represented by Harder, filed a $15 million libel lawsuit on similar grounds against Techdirt founder Mike Masnick and two other parties for a series of articles published beginning in September 2014. In February, Masnick, represented by the firm Prince Lobel, filed two motions to dismiss. One motion argued that the articles were constitutionally protected opinion and written about a public figure without actual malice. The second motion asked for dismissal under California's anti-SLAPP law that compensates defendants for some legal expenses. In September 2017, United States District Judge F. Dennis Saylor dismissed the defamation claims against Techdirt, but declined to strike the complaint under the anti-SLAPP law. In his ruling, Saylor wrote that definitions of "email" vary widely. Therefore, "whether plaintiff's claim to have invented e-mail is 'fake' depends upon the operative definition of 'e-mail.' Because the definition does not have a single, objectively correct answer, the claim is incapable of being proved true or false." The two parties filed cross-appeals with the U.S. Court of Appeals for the First Circuit but settled out of court in May 2019, with each side agreeing to pay their own legal costs and Techdirt's articles to remain online with an added link to a rebuttal on Ayyadurai's website.

== Early life and education == Crick was the first son of Harry Crick and Annie Elizabeth Crick (née Wilkins). He was born on 8 June 1916 and raised in Weston Favell, then a small village near the English town of Northampton, in which Crick's father and uncle ran the family's boot and shoe factory. His grandfather, Walter Drawbridge Crick, an amateur naturalist, wrote a survey of local foraminifera (single-celled protists with shells), corresponded with Charles Darwin, and had two gastropods (snails or slugs) named after him. At an early age, Francis was attracted to science and what he could learn about it from books. As a child, he was taken to church by his parents. But by about age 12, he said he did not want to go any more as he preferred a scientific search for answers over religious belief. Walter Crick, his uncle, lived in a small house on the south side of Abington Avenue; he had a shed at the bottom of his little garden where he taught Crick to blow glass, do chemical experiments and to make photographic prints. When he was eight or nine he transferred to the most junior form of the Northampton Grammar School, on the Billing Road. This was about 1.25 mi (2 km) from his home so he could walk there and back, by Park Avenue South and Abington Park Crescent, but he more often went by bus or, later, by bicycle. The teaching in the higher forms was satisfactory, but not as stimulating. After the age of 14, he was educated at Mill Hill School in London (on a scholarship), where he studied mathematics, physics, and chemistry with his best friend John Shilston.

Sources: en.wikipedia.org

Notes from published material

=== Valve Corporation v. Zaiger, LLC === In 2023, Valve sued a law firm, Zaiger, alleging that it attempted to extort settlements from Valve by threatening to bring numerous antitrust arbitration cases on behalf of Steam customers, a tactic referred to as "mass arbitration". Valve also brought suit against a litigation financier for Zaiger over the funding of a social media campaign to recruit Steam users as clients. Valve alleged that it improperly interfered with its contracts with Steam customers and abused the arbitration process by signing up clients with the intent of obtaining settlements slightly lower than the cost of arbitration filing fees, rather than arbitrating their claims. Valve said that it was targeted due to the terms of the Steam Subscriber Agreement, in which Valve would be responsible for the fees and costs associated with arbitration. The lawsuit was dismissed without prejudice by the US District Court for the Western District of Washington in 2024 due to personal jurisdiction issues. In September 2024, Valve changed its Steam Subscriber Agreement to require disputes to proceed in court, specifically in King County, Washington, with no option of arbitration.

General Cao, L. (2014). Behavior Informatics: A New Perspective. IEEE Intelligent Systems (Trends and Controversies), 29(4): 62–80. Clemons, E. K. (2008). "How Information Changes Consumer Behavior and How Consumer Behavior Determines Corporate Strategy". Journal of Management Information Systems. 25 (2): 13–40. doi:10.2753/mis0742-1222250202. S2CID 16370526. Dowhan, D (2013). "Hitting Your Target". Marketing Insights. 35 (2): 32–38. Perner, L. (2008), Consumer behavior. University of Southern California, Marshall School of Business. Retrieved from http://www.consumerpsychologist.com/intro_Consumer_Behavior.html Szwacka-Mokrzycka, J (2015). "TRENDS IN CONSUMER behavior CHANGES. OVERVIEW OF CONCEPTS". Acta Scientiarum Polonorum. Oeconomia. 14 (3): 149–156.

== Human proteins containing this domain == SLC6A1, SLC6A2, SLC6A3, SLC6A4, SLC6A5, SLC6A6, SLC6A7, SLC6A8, SLC6A9, SLC6A11, SLC6A12, SLC6A13, SLC6A14, SLC6A15, SLC6A16, SLC6A17, SLC6A18, SLC6A19, SLC6A20

The word petroleum comes from Medieval Latin petroleum (literally 'rock oil'), which comes from Latin petra 'rock' (from Greek pétra πέτρα) and oleum 'oil' (from Greek élaion ἔλαιον). The origin of the term stems from monasteries in southern Italy where it was in use by the end of the first millennium as an alternative for the oldest term "naphtha". After that, the term was used in numerous manuscripts and books, such as in the treatise De Natura Fossilium, published in 1546 by German mineralogist Georg Bauer. After the advent of the oil industry during the second half of the 19th century, the term became commonly known for the liquid form of hydrocarbons.

Sources: en.wikipedia.org

Frequently asked questions

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Why is AOD-9604 discussed in anti-doping?

It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.

What did human trials of AOD-9604 find?

Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

Network